e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The predictive value of total vs. amplificable free-circulating DNA in plasma of NSCLC patients – a preliminary study
R. Struniawski, A. Szpechcinski, J. Zaleska, M. Chabowski, T. Orlowski, K. Roszkowski, E. Rogala, J. Chorostowska-Wynimko (Warsaw, Poland)
Source:
Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Session:
Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Session type:
Thematic Poster Session
Number:
3550
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Struniawski, A. Szpechcinski, J. Zaleska, M. Chabowski, T. Orlowski, K. Roszkowski, E. Rogala, J. Chorostowska-Wynimko (Warsaw, Poland). The predictive value of total vs. amplificable free-circulating DNA in plasma of NSCLC patients – a preliminary study. Eur Respir J 2008; 32: Suppl. 52, 3550
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
The clinical significance of plasma DNA quantification in NSCLC
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011
PTGER4, a promising novel DNA methylation marker for lung cancer measured in a clinical case control study using blood plasma
Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Year: 2008
The detection of quantitative serum p53 protein in lung cancer and its clinical value
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients
Source: Eur Respir J 2001; 18: Suppl. 33, 377s
Year: 2001
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients.
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
Source: Eur Respir J 2015; 46: 1773-1780
Year: 2015
Immunological factors in NSCLC patients with possible predictive and prognostic value under PDL-1 treatment-a pilot study
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Real-time PCR analysis of free-circulating DNA in plasma of non-small cell lung cancer patients
Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer
Year: 2009
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Hypermethylation pattern in genomic DNA samples derived from tumor and serum of resected non-small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)?
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool
Source: Annual Congress 2012 - New insights in the pathology of lung cancer
Year: 2012
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005
Loss of heterozygosity detected in plasma DNA of early stage lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 673s
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept